These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21460383)

  • 21. Development and validation of a new instrument to measure perceived risks associated with the use of tobacco and nicotine-containing products.
    Cano S; Chrea C; Salzberger T; Alfieri T; Emilien G; Mainy N; Ramazzotti A; Lüdicke F; Weitkunat R
    Health Qual Life Outcomes; 2018 Sep; 16(1):192. PubMed ID: 30241527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple tobacco product use among US adolescents and young adults.
    Soneji S; Sargent J; Tanski S
    Tob Control; 2016 Mar; 25(2):174-80. PubMed ID: 25361744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing and Validating Measures of Absolute and Relative E-Cigarette Product Risk Perceptions: Single Items Can Be Surprisingly Comprehensive.
    O'Brien EK; Baig SA; Persoskie A
    Nicotine Tob Res; 2022 Feb; 24(3):316-323. PubMed ID: 34343322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further amendments to general regulations of the Food and Drug Administration to incorporate tobacco products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Feb; 77(22):5171-6. PubMed ID: 22359802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology.
    Brandon TH; Goniewicz ML; Hanna NH; Hatsukami DK; Herbst RS; Hobin JA; Ostroff JS; Shields PG; Toll BA; Tyne CA; Viswanath K; Warren GW
    J Clin Oncol; 2015 Mar; 33(8):952-63. PubMed ID: 25572671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory issues concerning the development and circulation of nicotine-containing products: a qualitative study.
    Rooke C; McNeill A; Arnott D
    Nicotine Tob Res; 2013 Jun; 15(6):1052-9. PubMed ID: 23128517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA's misplaced priorities: premarket review under the Family Smoking Prevention and Tobacco Control Act.
    Jenson D; Lester J; Berman ML
    Tob Control; 2016 May; 25(3):246-53. PubMed ID: 27068243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consumer and health literacy: The need to better design tobacco-cessation product packaging, labels, and inserts.
    Weiss SM; Smith-Simone SY
    Am J Prev Med; 2010 Mar; 38(3 Suppl):S403-13. PubMed ID: 20176315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing modified risk tobacco and nicotine products: Description of the scientific framework and assessment of a closed modular electronic cigarette.
    Murphy J; Gaca M; Lowe F; Minet E; Breheny D; Prasad K; Camacho O; Fearon IM; Liu C; Wright C; McAdam K; Proctor C
    Regul Toxicol Pharmacol; 2017 Nov; 90():342-357. PubMed ID: 28954704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tobacco, public health, and the FDA.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2009 Jul; 361(4):402-3. PubMed ID: 19546344
    [No Abstract]   [Full Text] [Related]  

  • 31. Food and Drug Administration tobacco regulation and product judgments.
    Kaufman AR; Finney Rutten LJ; Parascandola M; Blake KD; Augustson EM
    Am J Prev Med; 2015 Apr; 48(4):445-51. PubMed ID: 25726094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should the FDA regulate nicotine-containing cigarettes? Has the Agency established a legal basis and, if not, should congress grant it?
    Carchman SH
    Food Drug Law J; 1996; 51(1):85-138. PubMed ID: 11794355
    [No Abstract]   [Full Text] [Related]  

  • 33. Tobacco company efforts to influence the Food and Drug Administration-commissioned Institute of Medicine report clearing the smoke: an analysis of documents released through litigation.
    Tan CE; Kyriss T; Glantz SA
    PLoS Med; 2013; 10(5):e1001450. PubMed ID: 23723740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The First 10 Years: Reflecting on Opportunities and Challenges of the Tobacco Products Scientific Advisory Committee of the United States Food and Drug Administration.
    Fagan P; Eissenberg T; Jones DM; Cohen JE; Nez Henderson P; Clanton MS
    J Leg Med; 2020; 40(3-4):293-320. PubMed ID: 33797324
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
    Kozlowski LT
    Am J Prev Med; 2007 Dec; 33(6 Suppl):S379-86. PubMed ID: 18021913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential effects of using non-combustible tobacco and nicotine products during pregnancy: a systematic review.
    Glover M; Phillips CV
    Harm Reduct J; 2020 Mar; 17(1):16. PubMed ID: 32122384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constructive cigarette regulation.
    Viscusi WK
    Duke Law J; 1998 Apr; 47(6):1095-131. PubMed ID: 10557546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interventions to reduce harm from continued tobacco use.
    Lindson-Hawley N; Hartmann-Boyce J; Fanshawe TR; Begh R; Farley A; Lancaster T
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005231. PubMed ID: 27734465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nicotine Reduction Strategy: State of the science and challenges to tobacco control policy and FDA tobacco product regulation.
    Benowitz NL; Henningfield JE
    Prev Med; 2018 Dec; 117():5-7. PubMed ID: 29944901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticipating Industry Arguments: The US Food and Drug Administration's Authority to Reduce Nicotine Levels in Cigarettes.
    Berman ML; Zettler PJ; Ashley DL
    Public Health Rep; 2018; 133(4):502-506. PubMed ID: 29879366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.